With 44 million consumers banging on its door, and $950 million of revenue projected over the next three years, New Jersey’s adult use marijuana program is poised to define cannabis across the eastern seaboard.
Currently comprised of merely 95,000 patients and 12 alternative treatment centers (ATCs) to serve its 9,241,900 population, New Jersey’s decade-old medical marijuana program is both under performing and mired by ludicrous limitations and legal challenges.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]